Frequency Therapeutics hosted a virtual investor event on December 13, 2022. The primary focus was FX-322, the Company’s lead hearing restoration candidate for acquired sensorineural hearing loss (SNHL). Company management reviewed the FX-322 Phase 2b study design, the patient populations targeted for enrollment, pre-specified speech perception endpoints, and the potential FX-322 commercial market opportunity. Key opinion leaders (KOLs) also provided insight into the potential impact of a pharmaceutical intervention for patients with SNHL, how a medicine for cochlear regeneration may fit with currently available hearing devices, and the clinical significance of speech perception on overall hearing.